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Abstract
Background: Long-chain n-3 polyunsaturated fatty acids (LC n-3-PUFA), docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) provide multiple health benefits for heart, brain and eyes. However, consumption of
fatty fish, the main source of LC n-3-PUFAs is low in Western countries. Intakes of LC n-3-PUFA can be increased
by taking dietary supplements, such as fish oil, algal oil, or krill oil. Recently, conflicting information was published
on the relative bioavailability of these omega-3 supplements. A few studies suggested that the phospholipid form (krill)
is better absorbed than the fish oil ethyl ester (EE) or triglyceride (TG) forms. Yet studies did not match the
doses administered nor the concentrations of DHA and EPA per supplement across such comparisons, leading
to questionable conclusions. This study was designed to compare the oral bioavailability of the same dose of
both EPA and DHA in fish oil-EE vs. fish oil-TG vs. krill oil in plasma at the end of a four-week supplementation.
Methods: Sixty-six healthy adults (n = 22/arm) were enrolled in a double blind, randomized, three-treatment,
multi-dose, parallel study. Subjects were supplemented with a 1.3 g/d dose of EPA + DHA (approximately
816 mg/d EPA + 522 mg/d DHA, regardless of formulation) for 28 consecutive days, as either fish oil-EE, fish
oil-TG or krill oil capsules (6 caps/day). Plasma and red blood cell (RBC) samples were collected at baseline
(pre-dose on Day 1) and at 4, 8, 12, 48, 72, 336, and 672 h. Total plasma EPA + DHA levels at Week 4 (Hour 672) were
measured as the primary endpoint.
Results: No significant differences in total plasma EPA + DHA at 672 h were observed between fish oil-EE
(mean = 90.9 ± 41 ug/mL), fish oil-TG (mean = 108 ± 40 ug/mL), and krill oil (mean = 118.5 ± 48 ug/mL), p = 0.052 and
bioavailability differed by <24 % between the groups. Additionally, DHA + EPA levels were not significantly different in
RBCs among the 3 formulations, p = 0.19, providing comparable omega-3 indexes.
Conclusions: Similar plasma and RBC levels of EPA + DHA were achieved across fish oil and krill oil products when
matched for dose, EPA, and DHA concentrations in this four week study, indicating comparable oral bioavailability
irrespective of formulation.
Trial registration: Clinicaltrials.gov identifier NCT02427373.
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Introduction
The positive benefits of long-chain n-3 polyunsaturated
fatty acids (LC n-3-PUFA), docosahexaenoic acid (DHA)
and eicosapentaenoic acid (EPA) for heart, brain and eye
health are supported by many clinical studies [1–4].
However consumption of LC n-3-PUFA in the Western
diet is low [5]. While no recommended daily intake
for LC n-3-PUFA exists, authoritative bodies such as
the Academy of Nutrition and Dietetics recommend
500 mg/d for cardiovascular health [6]. Intakes of
LC n-3-PUFA can be increased by greater fish con-
sumption or by taking dietary supplements, such as
fish oil, algal oil or krill oil. Recently there has been
conflicting and confusing information published on
the relative oral bioavailability of these omega-3 sup-
plements with a few studies suggesting that the
phospholipid form (krill) is better absorbed than the
ethyl ester (EE) or triglyceride (TG) forms of fish
oils [7, 8]. Yet some studies did not match the doses
administered, the number of capsules provided, and/
or the amounts of DHA and EPA per supplement [7–11].
An open label study by Ulven, et al. [8] supplemented
adults for seven weeks with nonequivalent doses of either
krill oil (3 g/d) or fish oil TG (1.8 g/d) compared to a con-
trol (non- supplemented) group. The total EPA +DHA
concentration and number of capsules administered were
also not matched, making comparative bioavailability of
these oils difficult. Schuchardt et al. [9] conducted an
acute crossover bioavailability study comparing a single
dose (1.68 g) of fish oil TG, EE and krill oil but the total
concentration of each fatty acid, DHA and EPA was not
equal between formulations. In order to reach a compar-
able total dose of EPA +DHA, subjects consumed 14 cap-
sules of krill oil compared to 4 capsules of the fish oil.
This was a single-dose kinetic study with the last
sample collected at 72 h. The benefits of LC n-3-PUFA
are based on chronic consumption. Therefore, it is
important to assess levels of DHA and EPA after longer
term use. Arterburn et al. [12] demonstrated that steady
state plasma levels of LC n-3-PUFA were achieved after
4 weeks.
The objective of this double-blind, randomized, three-
treatment, multi-dose, parallel study was to compare
the relative oral bioavailability of a 1.3 g/d dose of
DHA + EPA in the form of fish oil-EE vs. fish oil-TG
vs. krill oil. The study was designed to test the
hypothesis that total plasma levels of DHA + EPA
would not be significantly different between the for-
mulations at Week 4. Total dose of EPA and DHA
was approximately 816 mg/d and 522 mg/d, respectively
regardless of formulation. The primary outcome was to
assess and compare the total plasma levels of EPA +DHA
across all 3 treatments at the end of the 4-week (Hour
672) study.
Methods
Study population and study design
Figure 1 provides a flow chart of subject disposition.
One hundred-five healthy adults were recruited and
screened via advertising and clinic database review.
Sixty-six healthy adults were randomly assigned to one
of the 3 formulations in the study. The study was
approved by IntegReview IRB, Austin TX and was con-
ducted in accordance with the clinical research guide-
lines as defined in the U.S. 21 CFR Parts 50, 56, and
ICH E6, and the principles enunciated in the Declaration
of Helsinki. All subjects provided written informed con-
sent prior to undergoing any study-specific procedures.
Major criteria for Inclusion: healthy male or females
(not pregnant nor breastfeeding), 18–60 years of age
(inclusive), with a body mass index between 18 and
30 kg/m2 (inclusive), and minimum weight of 50 kg
(110 lb). Major exclusion criteria included a history or
presence of diabetes, high triglycerides (≥240 mg/dL), or
high cholesterol (≥240 mg/dL); history or presence of
allergic or adverse response to omega-3-acids or sensi-
tivity or allergy to fish or shellfish; history of coagulation
disorder or current anticoagulation therapy; use of any
nutritional supplements, omega-3 supplements, fish oil,
chia, krill oil, or flaxseed within 3 months prior to the
first dose of study product; consumed walnuts or any
other food product supplemented with omega-3 fatty
acids (e.g., orange juice) or fatty fish >2 times per week
within 14 days prior to the first dose; history or presence
of any major, clinically significant disease or condition.
Subjects were admitted to the research unit 24 h prior to
study product administration and remained at the unit
until 12 h after the first dose on Day 1. Subjects continued
daily dosing over 28 consecutive days (4 weeks). Plasma
and red blood cell (RBC) samples were collected at base-
line (pre-dose on Day 1), and at 4, 8, 12, 48, 72, 336, and
672 h after dosing for fatty acid analyses. Fasting blood
draws were taken pre-dose and at hour 672. A standard
high fat meal was administered prior to first dose of study
product. Vital signs and clinical lab values (including
lipids) were measured during and at the end of the
study, respectively. Dietary intake of omega-3 fatty
acids was reported on a food frequency questionnaire
(FFQ) [13] at each in-clinic visit (for a total of 6
visits) and subjects were provided a list of foods that
should not be consumed during the course of the study.
Any reported adverse events (AEs) were recorded.
Study products
All subjects consumed 6 capsules/day for 4 weeks. The
krill oil product used (Euphausia superba) was com-
mercially available NutriGold™ Double Strength Krill
Gold oil (Neptune Technologies and Bioresources Inc,
Laval, PQ). Krill capsules contained the antioxidant,
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astaxanthin, 840 μg/cap. Lipid class analysis of the krill oil
capsule content as determined by TLC separation and fatty
acid analysis of fractions indicated 44 % (w/w) phospho-
lipid, 40 % triglyceride, 10 % diglyceride, 5 % sterol ester
and 2 % free fatty acid (DSM, internal analysis). Fish
oil-TG was commercially available Meg-3 1408 natural
TG (DSM Nutritional Products, Mulgrave, NS). Fish
oil-EE was Meg-3 1408 ethyl ester (DSM Nutritional
Products, Mulgrave, NS). Fish oil capsules contained
mixed natural tocopherol (1 mg/g) as antioxidant in
the form of Tocoblend L70 IP (Vitablend, Wolvega,
Netherlands) and paprika colorant RE04 (NutriCorp
International, Windsor, ON) to match the krill oil. The
following capsule fill weights and EPA +DHA content/
capsule are listed below.
 Krill oil capsule fill weight = 1147 mg
EPA = 135 mg/cap + DHA = 81 mg/cap
 Meg-3 1408 ethyl ester capsule fill weight = 1149 mg
EPA = 140 mg/cap + DHA = 90 mg/cap
 Meg-3 1408 natural TG capsule fill weight = 1145 mg
EPA = 140 mg/cap +DHA= 90 mg/cap
Fatty acid analyses
Total lipids were extracted from 500 μL of packed RBCs
using the method of Bligh and Dyer [14]. Plasma total
lipids were extracted from 400 μL of plasma using the
methods of Folch [15]. Tricosanoic free fatty acid (23:0)
was added to each sample as an internal standard. All
lipids were saponified with 0.5 N methanolic sodium
hydroxide and the fatty acids were converted to methyl
esters with 14 % BF3/methanol at 100 °C for 30 min
[16]. Fatty acid methyl esters were analyzed by GLC
using a Hewlett Packard 6890 equipped with a flame
ionization detector. The fatty acid methyl esters were
separated on a 30 m FAMEWAX capillary column
(Restek, Bellefonte, PA; 0.25 mm diameter, 0.25 μm coat-
ing thickness) using hydrogen at a flow rate of 2.1 mL/
min with a split ratio of 48:1. The chromatographic run
parameters included an oven starting temperature of
130 °C that was increased at 6 °C/min to 225 °C, where
it was held for 20 min before increasing to 250 °C at
15 °C/min, with a final hold of 5 min. The injector
and detector temperatures were constant at 220 °C and
230 °C, respectively. Peaks were identified by comparison
of retention times with external fatty acid methyl ester
standard mixtures from NuCheck Prep (Elysian, MN).
Statistical analyses
The primary outcome variable was the total plasma
DHA + EPA concentration at Week 4 (Hour 672, fasted
state). With an anticipated dropout rate of 10 %, it was
expected that 60 completed subjects (approximately 20/
group) would show no significant differences in total
plasma DHA + EPA levels between the 3 formulations
and would allow a determination of comparable bioavail-
ability [10]. Differences between the plasma concen-
trations of DHA + EPA across the three nutritional
supplements were determined by analysis of covari-
ance (ANCOVA) modeling. The model included the
pre-dose value as a covariate. The primary analysis
was performed using the intent to treat population.
The secondary analyses included comparisons of the
concentrations of DHA+ EPA in RBCs and concentrations
Fig. 1 Disposition of subjects
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of DHA and EPA separately in plasma and RBCs across
nutritional supplements, using an analogous ANCOVA
model; these analyses were performed using the intent to
treat and per protocol populations. Analyses of demo-
graphic and screening variables were analyzed by ANOVA
for between group differences of continuous variables or
by chi-square tests for categorical variables. All tests
of significance were performed at α = 0.05, 2-sided. As
supportive evidence of comparable systemic exposure,
concentrations of DHA+ EPA, DHA, and EPA in plasma
and RBCs were also compared across treatments in a
pairwise manner, analogous to the analyses performed
in bioequivalence assessments [17]. The two one-sided
t-tests procedure was utilized to perform comparisons
of fish oil-EE vs. fish oil-TG vs. krill oil levels at Week 4.
The geometric mean ratios (GMR) and 90 % confidence
intervals were presented for each comparison.
Study product compliance was measured by capsule
counts and by the change in plasma EPA +DHA fatty acid
levels from Hour 672 to pre-dose of ≥ 10 ug/mL. Changes
less than 10 ug/mL or negative values were considered
non-compliant.
All statistical analyses were conducted using SAS®
(version 9.3, SAS Institute, Inc.).
Results
Subject characteristics
Sixty-six healthy adults (n = 22/arm) completed the study,
overall mean ± SEM age = 35 (±1.4) years; 73 % were fe-
male, 59 % were Hispanic, mean weight = 68.7 (±1.4) kg,
mean BMI = 25 (±0.3) kg/m2. Demographic characteristics
of the 3 groups are shown in Table 1. No differences in
any of these characteristics were found between the
groups. Baseline vitals and ECG parameters were normal
with no differences detected among the groups (data not
shown). Dietary intake of omega-3 fatty acids, DHA, and
EPA, as measured by the FFQ [13], showed low consump-
tion at baseline, with an overall group mean ± SEM of
DHA + EPA =89.5 (±7.2) mg/d; no significant differences
between the groups were observed, p = 0.34. Over the
course of the 4 week study, dietary intake of DHA+ EPA
declined to an average of 50–71 mg/d across the three
groups, as assessed by the FFQ (p = 0.039). Pre-dose (base-
line) total plasma mean (±SEM) DHA + EPA levels were
not significantly different among the three groups (fish
oil-EE 41.5 ± 3.3 ug/mL, fish oil-TG 42.7 ± 3.5 ug/mL, krill
oil 37.5 ± 2.9 ug/mL, p = 0.51).
Compliance with the study product was estimated at
100 % by capsule count and 93.9 % overall by change in
plasma DHA + EPA levels (Hour672 -baseline ≥10 ug/mL).
Four subjects (3 given fish oil-TG; 1 given krill oil)
were removed in the per protocol analyses due to non-
compliance with study product or consumption of foods
supplemented with omega-3 fatty acids.
Bioavailability of DHA + EPA in plasma, week 4
Mean (±SD) DHA + EPA plasma concentrations at Week
4 (Fig. 2) were not significantly different between the
three groups (90.99 ± 41.45 ug/mL fish oil-EE, 108.07 ±
40.41 ug/mL fish oil-TG, and 118.59 ± 48.74 ug/mL krill
oil), p = 0.052, demonstrating similar bioavailability. Bio-
availability of the three products differed by less than
24 %. As shown in Fig. 2, mean plasma concentrations at
early time points (0–72 h) were also nearly identical be-
tween the groups. Pairwise comparisons of total DHA+
EPA plasma concentrations at Week 4, using the two
one-sided t-tests procedure, showed geometric mean
ratios (90 % confidence intervals) as: 0.75 (0.59, 0.96) for
fish Oil -EE vs. krill oil; 0.82 (0.64, 1.04) for fish oil-EE vs.
fish oil-TG; and 0.92 (0.73, 1.15) for fish oil-TG vs. krill oil.
Bioavailability of EPA or DHA in plasma, week 4
All three formulations had a higher EPA content relative
to DHA, with an EPA:DHA ratio of approximately 1.6:1.
Therefore, the bioavailability of each of these individual
fatty acids was determined separately, in addition to the
EPA +DHA previously presented. As shown in Fig. 3a,
mean EPA plasma concentrations were similar at early
time points following the administration of fish oil-EE,
fish oil-TG, and krill oil. At Week 4, mean (±SD) EPA
plasma concentrations were 41.95 ± 26.22 ug/mL for fish
oil-EE, 50.07 ± 24.65 ug/mL for fish oil-TG, and 56.99 ±
30.40 ug/mL for krill oil, with no significant differences
detected between groups, p = 0.17, indicating similar bio-
availability. All pairwise comparisons of bioequivalence
at Week 4 did not meet criteria.
Similarly, overall mean DHA plasma concentrations
were comparable across the three groups. Differences
were noted between 336 and 672 h, during which time
the mean DHA plasma concentrations were similar for
krill oil and fish oil-TG, while that for fish oil-EE was
somewhat lower (Fig. 3b) and the Week 4 ANCOVA for
the three groups was significant, p = 0.013. A trend of
bioequivalence at Week 4 between fish oil-TG and krill
oil was found with a GMR = 0.95 (0.79, 1.13), p = 0.059.
Bioavailability of DHA + EPA and DHA or EPA alone in
RBCs, week 4
In RBCs, DHA + EPA levels were not significantly dif-
ferent between groups at Week 4 (fish oil-EE mean ±
SD =39.6 ± 13 ug/mL; fish oil-TG =44.5 ± 12 ug/mL;
krill oil =46.1 ± 13 ug/mL; p = 0.19, Fig. 4). The bio-
availability in RBCs, as a proxy for long-term intake
was comparable across treatments and differed overall
by less than 14 %. Pairwise comparisons of fish oil-
TG vs krill oil DHA + EPA RBC levels were signifi-
cant with a GMR = 0.96 (0.82, 1.12) demonstrating
comparable bioavailability. As seen in Fig. 4, pre-dose
(baseline) DHA + EPA RBC levels were not significantly
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Table 1 Demographic Characteristics




Ethyl Ester (N = 22)
Treatment B
Triglycerides (N = 22)
Treatment C
krill Oil (N = 22)
p-value*
Gender Female 48 (72.7 %) 17 (77.3 %) 13 (59.1 %) 18 (81.8 %) 0.2011
Male 18 (27.3 %) 5 (22.7 %) 9 (40.9 %) 4 (18.2 %)
Age (years) N 66 22 22 22 0.4523
Mean (SEM) 35.45 (1.44) 37.41 (2.69) 35.95 (2.39) 33.00 (2.42)
Std Dev 11.72 12.64 11.21 11.37
Min, Max 19.00, 57.00 19.00, 57.00 19.00, 52.00 19.00, 55.00
Ethnicity Not Hispanic or Latino 27 (40.9 %) 10 (45.5 %) 9 (40.9 %) 8 (36.4 %) 0.8286
Hispanic or Latino 39 (59.1 %) 12 (54.5 %) 13 (59.1 %) 14 (63.6 %)
Race Asian 1 (1.5 %) 1 (4.5 %) 0 (0.0 %) 0 (0.0 %) 0.6239
Black or African American 7 (10.6 %) 2 (9.1 %) 3 (13.6 %) 2 (9.1 %)
White 57 (86.4 %) 19 (86.4 %) 18 (81.8 %) 20 (90.9 %)
Mixed: White, Black or African American 1 (1.5 %) 0 (0.0 %) 1 (4.5 %) 0 (0.0 %)
Weight (kg) N 66 22 22 22 0.3480
Mean (SEM) 68.72 (1.43) 69.06 (2.83) 71.10 (2.55) 66.01 (1.96)
Std Dev 11.59 13.25 11.94 9.17
Min, Max 50.90, 111.20 50.90, 111.20 51.00, 89.00 52.80, 84.60
Height (cm) N 66 22 22 22 0.2408
Mean (SEM) 164.35 (1.16) 164.98 (2.47) 166.39 (1.80) 161.68 (1.63)
Std Dev 9.45 11.59 8.44 7.66
Min, Max 149.50, 194.00 149.50, 194.00 153.00, 179.50 149.50, 181.00
BMI (kg/m^2) N 66 22 22 22 0.9056
Mean (SEM) 25.32 (0.32) 25.22 (0.56) 25.53 (0.54) 25.22 (0.59)
Std Dev 2.60 2.62 2.54 2.75
Min, Max 19.80, 29.50 20.90, 29.50 20.80, 29.50 19.80, 29.20
*P-values were derived by ANOVA for continuous variables and by the Chi-square test for categorical variables
Fig. 2 Mean Plasma DHA + EPA Concentration-Time Profiles after Administration of fish oil-Ethyl Ester, fish oil-Triglyceride, and krill oil, on a Linear
Scale, Week 4 ANCOVA, p = 0.052, showing comparable bioavailability
Yurko-Mauro et al. Lipids in Health and Disease  (2015) 14:99 Page 5 of 9
different between the three groups (fish oil-EE mean ±
SEM = 26.3 ± 1.8 ug/mL, fish oil-TG = 27.6 ± 2.2 ug/mL,
krill oil = 25.9 ± 1.7, p = 0.79). Analyses of mean (±SD)
DHA RBC concentrations at Week 4 were not significantly
different (27.68 ± 8.47 ug/mL for fish oil-EE, 30.59 ± 7.54
ug/mL for fish oil-TG, and 30.06 ± 7.37 ug/mL for
krill, p = 0.48). Pairwise comparisons of fish oil-TG vs
krill DHA RBC levels were significant with a GMR =
1.01 (0.89, 1.15) showing comparable bioavailability
between these two products. While mean (±SD) EPA
RBC concentrations at Week 4 among the groups
were not significantly different (11.93 ± 6.04 ug/mL
a
b
Fig. 3 a Mean Plasma EPA Concentration-Time Profiles after Administration of fish oil-Ethyl Ester, fish oil-Triglyceride, and krill oil on a Linear Scale,
Week 4 ANCOVA, p = 0.17, showing comparable bioavailability. b Mean Plasma DHA Concentration-Time Profiles after Administration of fish oil-Ethyl
Ester, fish oil-Triglyceride, and krill oil on a Linear Scale. Week 4 ANCOVA, p = 0.013; a bioequivalence trend between fish oil-TG and krill oil is
shown, GMR = 0.95 (0.79,1.13), p = 0.059
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for fish oil-EE, 13.98 ± 5.64 ug/mL for fish oil-TG,
and 16.11 ± 7.16 ug/mL for krill oil, p = 0.07), overall
levels of EPA in RBCs were lower than DHA levels.
Safety parameters
No clinically significant abnormalities or changes in vital
signs or physical exams were observed over the course
of the study. No significant changes in clinical laboratory
tests, e.g. lipid panel parameters, glucose, or alkaline phos-
phatase, among others were noted. A total of 11 AEs were
reported by 9 subjects (5 AEs in the krill oil group; 3 AEs
in the fish oil-EE group; 3 AEs in the fish oil-TG group)
over the course of the study. No serious AEs were re-
ported. Table 2 shows the treatment–emergent AEs by
verbatim term and group. The most commonly reported
post-dose AEs were nausea (n = 2, both following fish oil-
EE supplementation), and headache (n = 2: 1 following fish
oil-TG supplementation and 1 following krill oil supple-
mentation). Gastrointestinal AEs (e.g. abdominal cramps,
bloating, gas) were minimal and were not different
between the groups in this study. Of note, there were no
instances of burping reported in any of the study groups.
Discussion
No significant differences in mean fasting plasma
concentrations of DHA + EPA, as a proxy for steady-
state LC n-3-PUFA levels, were found after four weeks of
supplementation of a 1.3 g/d dose of DHA+ EPA in fish
oil-EE, or fish oil-TG or krill oil, demonstrating compar-
able oral bioavailability (i.e. amount of active ingredient
absorbed). The results demonstrate <24 % difference in
bioavailability among the 3 products. The four week time
course of supplementation was chosen as this time period
typically demonstrates that omega-3 fatty acid plasma
levels reach plateau (as observed in Figs. 2, 3a, b and 4) in
healthy adults and is an estimate of steady-state levels and
representative of short term intake. Our results also show
nearly identical bioavailability among the groups at early
timepoints (<48 h) of the plasma time course, illustrating
no better bioavailability of one product versus another
when equivalent concentrations of omega-3 fatty acids are
administered. In contrast, a study by Kagan et al. [18]
showed significantly increased plasma concentrations of
EPA from an algal oil supplement compared to krill oil at
5–10 h post-supplementation with greater peak and total
systemic exposure parameters, likely reflecting the greater
EPA content of the algal product. Another single-dose,
acute bioavailability study very recently published [19]
found higher plasma phospholipid EPA and DHA levels at
72 h in krill oil vs. krill meal or fish oil, but did not find
Fig. 4 Mean Red Blood Cell DHA + EPA Concentration-Time Profiles after Administration of fish oil-Ethyl Ester, fish oil-Triglyceride, and krill
oil on a Linear Scale, Week 4 ANCOVA, p = 0.19, showing comparable bioavailability
Table 2 Treatment-emergent adverse events by first
occurrencea and verbatim term safety population
Fish or krill Oil: 1.3 g/d









Abdominal bloating 0 (0.0 %) 1 (4.5 %) 0 (0.0 %)
Abdominal cramps 0 (0.0 %) 1 (4.5 %) 0 (0.0 %)
Abdominal pain 0 (0.0 %) 0 (0.0 %) 1 (4.5 %)
Hair loss 0 (0.0 %) 0 (0.0 %) 1 (4.5 %)
Headache 0 (0.0 %) 1 (4.5 %) 1 (4.5 %)
Insect bite 1 (4.5 %) 0 (0.0 %) 0 (0.0 %)
Intermittent epistaxis 0 (0.0 %) 0 (0.0 %) 1 (4.5 %)
Intermittent vasovagal 0 (0.0 %) 0 (0.0 %) 1 (4.5 %)
Nausea 2 (9.1 %) 0 (0.0 %) 0 (0.0 %)
Total events 3 3 5
aSubjects may have had more than one adverse event. For these subjects, the
first occurrence of the AE was tabulated
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higher levels between the krill meal and fish oil, even
given the same dose with relatively equal amounts of
DHA and EPA. As Kohler [19] pointed out, this result
argues against an interpretation that phospholipids are
better absorbed than triglycerides and suggested that a
longer term supplementation study, measuring RBC
levels, was needed. As phospholipid levels represent
only one fraction of the total fatty acid profile, it may
also be important to measure changes in the other
lipid fractions or measure total plasma and erythrocyte
fatty acid changes over time.
No significant differences in mean RBC concentrations
of DHA+ EPA at week 4 were obtained between our three
formulations, again demonstrating similar bioavailability.
This is important as it shows an integrated picture of
DHA+ EPA utilization in the body and RBC levels are a
proxy for long-term bioavailability. The DHA+ EPA per-
cent of total RBC fatty acids, the omega-3 index, is an
important cardiac risk factor and our study demonstrates
that all these products provide adequate DHA + EPA
levels to achieve this benefit [20]. The geometric mean
ratio for DHA + EPA comparing fish oil-TG vs krill oil in
RBCs at Week 4 were significant, indicating comparable
bioavailability between these two products. For RBC DHA
levels only, all three oil formulations were equally
bioavailable. Since RBC fatty acid content is import-
antly related to tissue fatty acid status, these results sug-
gest no differences in bioavailability in tissues among
the fish oil formulations and krill oil in this 4 week
study.
Examination of the individual fatty acids, DHA and EPA
each showed comparable bioavailability in plasma levels at
Week 4 among the fish oil and krill oil products. However,
DHA concentrations at hours 336 and 672 were lower in
the fish oil-EE group compared to fish oil-TG or krill oil
groups, as seen in Fig. 3b. Other studies have indicated
lower plasma levels of DHA and/or EPA with fish oil-EE
administration versus re-esterified TG [9, 21, 22], suggest-
ing lower bioavailability and reduced functional outcomes,
e.g. triacylglycerol lowering with the EE form. However
not all studies have shown this effect and the
marketed product approved for hypertriglyceridemia,
Lovaza™ is a fish oil-EE formulation that significantly
reduces triacylglycerol.
Our study demonstrated comparable bioavailability
among the 3 formulations, however variability and wider
confidence intervals were observed, especially in the
plasma levels. This variability likely impacted the bio-
equivalence assessments among the groups and may be
due to inter-individual variability and the smaller sample
size in this parallel study. A larger study or one with a
cross-over design may further elucidate these findings.
Different results observed in other omega-3 studies
using krill oil and fish oil may be due to non-equivalent
doses or unmatched DHA and EPA concentrations, non-
compliance, especially when large numbers of capsules
were used, or confounders such as increased dietary intake
of omega-3 fatty acids [11, 23]. The compliance in our
study was over 90 % (measured by plasma fatty acids
levels and capsule counts) and dietary intake of omega-3s
was low in this study sample. The formulations were well
tolerated and no differences in gastrointestinal symptoms,
of which there were very few, were noted. It is possible
that the phospholipid content in krill oil may affect its bio-
availability, however krill oil composition in various com-
mercial products varies widely in phospholipid content
from approximately 19–81 % [24] and this has not been
systematically examined in longer-term dosing trials. The
krill oil used in our study contained 43.7 % phospholipid
(not a minor component) and demonstrated similar bio-
availability to both TG and EE fish oil forms.
In conclusion, our results demonstrate similar plasma
and RBC levels of EPA +DHA were achieved with fish oil
and krill oil products when matched for dose and EPA +
DHA content in this four week study, indicating compar-
able oral bioavailability irrespective of formulation.
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